Stock SNGX SOLIGENIX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Soligenix, Inc.

Equities

SNGX

US8342235053

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
0.427 USD +11.49% Intraday chart for Soligenix, Inc. -1.91% -43.61%
Apr. 15 Sector Update: Health Care Stocks Softer Late Afternoon MT
Apr. 15 Sector Update: Health Care Stocks Gain Monday Afternoon MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Soligenix Announces Pricing of $4.75 Million Public Offering
PR
Sector Update: Health Care Stocks Softer Late Afternoon
MT
Sector Update: Health Care Stocks Gain Monday Afternoon
MT
Soligenix Shares Rise After Active Ingredient in MarVax Gets US FDA's Orphan Drug Designation
MT
Soligenix Shares Rise After SuVax Gets Orphan Drug Designation from US FDA
DJ
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection
PR
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection
PR
Soligenix Announces Agreement on the Design of Second Confirmatory Placebo-Controlled Trial for Hybryte? with the European Medicines Agency
CI
Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency
PR
Soligenix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results
PR
Soligenix Announces Formation of Beh et s Disease Medical Advisory Board
AQ
Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board
CI
Soligenix to Present at The Microcap Conference
PR
FDA Grants Soligenix 'Fast Track' Designation for Dusquetide in the Treatment of Oral Lesions of Behcet's Disease
AQ
FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease
PR
FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease
CI
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
PR
Soligenix Announces Top-Line Results of the Phase 2A Study of Sgx302 (Synthetic Hypericin) in Patients with Mild-To-Moderate Psoriasis
CI
Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SNGX Stock
  4. News Soligenix, Inc.